Contact Us
Menu
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Events
News
Posts
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Events
News
Posts

AACR 2021: Improved LAG-3 humanized knock-in mouse model for assessment of mono- and combination therapy strategies for cancer treatment

Home News & Resources Posters AACR 2021: Improved LAG-3 humanized knock-in mouse model for assessment of mono- and combination therapy strategies for cancer treatment

AACR 2021: Improved LAG-3 humanized knock-in mouse model for assessment of mono- and combination therapy strategies for cancer treatment

Author: Huilin Li, Xiaofei Zhou, Dirui Li, Veronika Chromikova, Qingcong Lin

  • LAG-3 is a negative regulator of immunity, such that inhibition of LAG-3 enhances the anti-tumor effect of specific CD8+ T cells. 
  • Biocytogen generated a humanized B-hLAG-3 mouse model, and an improved humanized B-hPD-1/hPD-L1/hLAG-3 mouse model to study mono- and combination therapies. 
  • B-hLAG-3 and B-hPD-1/hPD-L1/hLAG-3 mice do not exhibit changes in the overall development, differentiation or distribution of individual leukocyte subpopulations isolated from blood, lymph node and spleen. 
  • Combination therapy of anti-LAG-3 antibodies with anti-PD-1 (or anti-PD-L1) antibodies in the B-hPD-1/hPD-L1/hLAG-3 MC38 tumor model demonstrates synergistic inhibitory effects.
  • B-hPD-1/hPD-L1/hLAG-3 mice are a powerful tool for preclinical assessment of novel therapeutics. 

Share:

    Please fill out the form below to request a download of this poster